О клинике
Назад
О клинике О нас Хадасса в цифрах История Фототур Схема территории Новости События
Отделения
Назад
Аллергология и иммунология Гастроэнтерология Гематология Генетика Гинекология Дерматология Инфекционные заболевания Кардиология Неврология Нейрохирургия Нефрология Онкология Ортопедия Отоларингология Офтальмология Педиатрия Пластическая хирургия Психиатрия Пульмонология Радиология Радиотерапия Реабилитология Сосудистая хирургия Стоматология Торакальная хирургия Урология Хирургия Челюстно-лицевая хирургия Эндокринология Ядерная медицина Редкие заболевания Трансплантация костного мозга
Врачи
Пациентам
Назад
Отзывы и истории успеха Медицинские брошюры Пошаговое руководство Болезни от А до Я Процедуры и услуги от А до Я Прейскурант лекарств
Специалистам
Назад
Стажировки
Контакты
info@hds.org.il +9722 560-9534
О клинике
Назад
О клинике О нас Хадасса в цифрах История Фототур Схема территории Новости События
Отделения
Назад
Аллергология и иммунология Гастроэнтерология Гематология Генетика Гинекология Дерматология Инфекционные заболевания Кардиология Неврология Нейрохирургия Нефрология Онкология Ортопедия Отоларингология Офтальмология Педиатрия Пластическая хирургия Психиатрия Пульмонология Радиология Радиотерапия Реабилитология Сосудистая хирургия Стоматология Торакальная хирургия Урология Хирургия Челюстно-лицевая хирургия Эндокринология Ядерная медицина Редкие заболевания Трансплантация костного мозга
Врачи
Пациентам
Назад
Отзывы и истории успеха Медицинские брошюры Пошаговое руководство Болезни от А до Я Процедуры и услуги от А до Я Прейскурант лекарств
Специалистам
Назад
Стажировки
Контакты
info@hds.org.il +9722 560-9534

Моше Гат

Отделение: Гематология
Должность: Гематолог, заведующий отделением гематологии
Языки: Английский, Иврит
Принимает: только взрослых
Написать в WhatsApp Записаться на прием

Образование

Выпускник медицинского факультета Еврейского университета (Иерусалим).
Ординатура в медицинском центре Dana-Farber Cancer Institute (Бостон, США), под руководством профессора Кеннета Андерсона, одного из наиболее известных в мире специалистов в области лечения миеломы.

Специализация

  • Лечение множественной миеломы
  • Лечение амилоидоза
  • CAR-T терапия

Профессиональная деятельность

Заведующий отделением гематологии клиники "Хадасса". Руководитель центра лечения амилоидоза.

Научные публикации

Belantamab Mafodotin in Relapsed/Refractory AL Amyloidosis: Real-World Multi-Center Experience and Review of the Literature
Nivolumab, Pomalidomide, and Elotuzumab Combination Regimens for Treatment of Relapsed and Refractory Multiple Myeloma: Results from the Phase 3 CheckMate 602 Study
Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma
Clinical evaluation and determinants of response to HBI0101 (BCMA CART) therapy in relapsed/refractory multiple myeloma
Immune Therapies in AL Amyloidosis-A Glimpse to the Future
Smouldering multiple myeloma: To seek or not to seek? To treat or not to treat. That is the question
Standardization of Molecular MRD Levels in AML Using an Integral Vector Bearing ABL and the Mutation of Interest
Pathway for the Diagnosis and Management of Cardiac Amyloidosis
Clonal Myeloid Dysplasia Following CAR T-Cell Therapy: Chicken or the Egg?
Amyloidogenic light chains impair plasma cell survival
Process of drug registration in Israel: the correlation between the number of discussions within the Ministry of Health and postapproval variations by EMA and/or FDA
Report of Consensus Panel 6 from the 11 th International Workshop on Waldenström's Macroglobulinemia on Management of Waldenström's Macroglobulinemia Related Amyloidosis
Early lymphocyte collection for anti-CD19 CART production improves T-cell fitness in patients with relapsed/refractory diffuse large B-cell lymphoma
Venetoclax in Relapse/Refractory AL Amyloidosis-A Multicenter International Retrospective Real-World Study
Desensitization protocol to lenalidomide: An effective and safe treatment modality for delayed hypersensitivity-induced rash in patients with multiple myeloma
An mTORC1 to HRI signaling axis promotes cytotoxicity of proteasome inhibitors in multiple myeloma
Do older patients truly benefit from advances in myeloma care?
Development and manufacture of novel locally produced anti-BCMA CAR T cells for the treatment of relapsed/refractory multiple myeloma: results from a phase I clinical trial
Feasibility of a Novel Academic BCMA-CART (HBI0101) for the Treatment of Relapsed and Refractory AL Amyloidosis
Clinical features, therapy patterns, outcomes and prognostic factors of solitary plasmacytomas: a report of the Israeli Myeloma Study Group
Monitoring Minimal Residual Disease in RUNX1-Mutated Acute Myeloid Leukemia
Randomized, placebo-controlled, phase 3 study of perifosine combined with bortezomib and dexamethasone in patients with relapsed, refractory multiple myeloma previously treated with bortezomib
Re-induction versus salvage for D14-resiudal acute myeloid leukemia: A retrospective multi-center study
CD24 Is a Prognostic Marker for Multiple Myeloma Progression and Survival
Rituximab, methotrexate, procarbazine and lomustine (R-MPL) for the treatment of primary Central nervous system lymphoma
Understanding the Bioactivity and Prognostic Implication of Commonly Used Surface Antigens in Multiple Myeloma
Preclinical evaluation and structural optimization of anti-BCMA CAR to target multiple myeloma
Dose-adjusted EPOCH-R is not superior to sequential R-CHOP/R-ICE as a frontline treatment for newly diagnosed primary mediastinal B-cell lymphoma: Results of a bi-center retrospective study
Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis
Suppression of multiple myeloma by mitochondrial targeting
Identification of resistance pathways and therapeutic targets in relapsed multiple myeloma patients through single-cell sequencing
Serum Hevylite® assay in the differential diagnosis of patients with high suspicion of AL Amyloidosis
Characteristics and outcome of multiple myeloma patients presenting with anaemia only: A retrospective multi-centre study
Venous Thromboembolism Prophylaxis with Low-Molecular-Weight Heparin in Primary Central Nervous System Lymphoma
Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial
Neurological misdiagnoses of lymphoma
The impact of anti-bacterial prophylaxis on the outcome of patients treated with venetoclax-based regimens for relapsed/refractory plasma cell dyscrasias: Real-life data
Bortezomib Maintenance Therapy as a Standard of Care Provides Favorable Outcomes in Newly Diagnosed Myeloma Patients: A Multisite Real-Life Study
Ixazomib-based regimens for relapsed/refractory multiple myeloma: are real-world data compatible with clinical trial outcomes? A multi-site Israeli registry study
Bone marrow blast elimination by the fifth day of 7 + 3 induction is the strongest predictor of potential cure in patients with acute myeloid leukemia younger than 61 years of age: A long-term follow-up of a multi-center prospective study
The role of CD24 in multiple myeloma tumorigenicity and effects of the microenvironment on its expression
Evaluation of cerebrospinal clonal gene rearrangement in newly diagnosed non-Hodgkin's lymphoma patients
Romidepsin-Bendamustine Combination for Relapsed/Refractory T Cell Lymphoma
Addition of high-dose methotrexate to standard treatment for patients with high-risk diffuse large B-cell lymphoma contributes to improved freedom from progression and survival but does not prevent central nervous system relapse
Single cell dissection of plasma cell heterogeneity in symptomatic and asymptomatic myeloma
A Bortezomib-Based Protocol Induces a High Rate of Complete Remission with Minor Toxicity in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia
The use of serum free light chain dimerization patterns assist in the diagnosis of AL amyloidosis
Treatment patterns and clinical outcomes in high-risk newly diagnosed multiple myeloma patients carrying the 17p deletion: An observational multi-center retrospective study
Primary plasma cell leukemia in the era of novel agents for myeloma - a multicenter retrospective analysis of outcome
Daratumumab resistance is frequent in advanced-stage multiple myeloma patients irrespective of CD38 expression and is related to dismal prognosis
Gastrointestinal perforation in light chain amyloidosis in the era of novel agent therapy - a case series and review of the literature
Progressive refractory light chain amyloidosis and multiple myeloma patients are responsive to the addition of clarithromycin to IMiD based therapy
The prognostic value of bone marrow involvement at the molecular level in aggressive lymphoma
Favorable outcome of primary mediastinal large B-cell lymphoma patients treated with sequential RCHOP-RICE regimen without radiotherapy
Efficacy and safety of salvage therapy using Carfilzomib for relapsed or refractory multiple myeloma patients: a multicentre retrospective observational study
A Randomized Controlled Study to Determine the Efficacy of Garlic Compounds in Patients With Hematological Malignancies at Risk for Chemotherapy-Related Febrile Neutropenia
Thymidine kinase levels correlate with prognosis in aggressive lymphoma and can discriminate patients with a clinical suspicion of indolent to aggressive transformation
Outcomes of light-chain amyloidosis patients treated with first-line bortezomib: a collaborative retrospective multicenter assessment
Higher infection rate after 7- compared with 5-day cycle of azacitidine in patients with higher-risk myelodysplastic syndrome
Phase I/II study exploring ImMucin, a pan-major histocompatibility complex, anti-MUC1 signal peptide vaccine, in multiple myeloma patients
Polymorphisms in the human organic cation transporter and the multidrug resistance gene: correlation with imatinib levels and clinical course in patients with chronic myeloid leukemia
Bortezomib-induced peripheral neuropathy is related to altered levels of brain-derived neurotrophic factor in the peripheral blood of patients with multiple myeloma
Influence of ethnicity and improved outcome of acute myeloid leukaemia: two decades of follow-up of Israeli patient cohort
Short communication: bendamustine-related hemolytic anemia in chronic lymphocytic leukemia
Colistin is relatively safe in hematological malignancies and hematopoietic stem cell transplantation patients
TRIM13 (RFP2) downregulation decreases tumour cell growth in multiple myeloma through inhibition of NF Kappa B pathway and proteasome activity
Increased risk of central venous catheter-associated thrombosis in acute promyelocytic leukemia: a single-institution experience
Predicting infections in high-risk patients with myelodysplastic syndrome/acute myeloid leukemia treated with azacitidine: a retrospective multicenter study
Light chain amyloidosis 2012: a new era
High incidence of skin rash in patients with hairy cell leukemia treated with cladribine
MicroRNAs 15a/16-1 function as tumor suppressor genes in multiple myeloma
Central nervous system prophylaxis in mantle cell lymphoma
BCL9 promotes tumor progression by conferring enhanced proliferative, metastatic, and angiogenic properties to cancer cells
Prolonged fever, hepatosplenomegaly, and pancytopenia in a 46-year-old woman
Clinical problem-solving. A fractured diagnosis
Is prolonged immobilization a risk factor for symptomatic venous thromboembolism in elderly bedridden patients? Results of a historical-cohort study
Prolonged ileus as a sole manifestation of pseudomembranous enterocolitis
Chest radiographs in the emergency department: is the radiologist really necessary?
Chronic lymphocytic leukemia presenting with extreme hyperleukocytosis and thrombosis of the common femoral vein
Acute myocardial infarction after bone marrow transplantation: an unsuspected late complication
Treatment of tobacco use and dependence
Effect of serum amyloid A on selected in vitro functions of isolated human neutrophils
Показать ещё 74 статьи Скрыть статьи
Заболевания
Амилоидоз
Истинная полицитемия
Криоглобулинемия
Множественная миелома
Остеосклеротическая миелома
Показать ещё
Миелоидные опухоли
POEMS-синдром
Болезнь Кастлемана
Болезни тяжелых цепей
Болезнь депозитов легких цепей
Процедуры
Трансплантация костного мозга
Tерапия CAR-T-клетками
Терапия ингибиторами JAK

Новости

Мировые новости медицины, Новости «Хадассы» CAR-T терапия, разработанная в Хадассе получает одобрение FDA
Мировые новости медицины Лекарство для лечения амилоидоза
Смотреть все новости
Остались вопросы?
Напишите нам и мы свяжемся с вами в течение ближайшего времени и ответим на все интересующие вопросы